Reimbursement Briefs: ESRD Drugs, Medicare Data, Rx Adherence, Cancer Drug Value
Executive Summary
Physician patch bill delays including oral ESRD drugs in bundled Medicare payments until 2024; ASCO working on method to score relative value of cancer drugs, and more news in brief.
You may also be interested in...
Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix
In legislation passed by both chambers of Congress Jan. 1, the cost of a one-year reprieve from sharp cuts to Medicare physician payments, scheduled to begin in 2013, would be offset by a reduction in Medicare’s bundled payment for end-stage renal disease. The reduced payment would take into account a drop in the use of erythropoiesis-stimulating agents observed over the last several years.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.